future of glp 1 Why GLP-1 drugs are changing the metabolic health Emerging Trends in the Development

Patients who inadvertently use medication beyond the recommended timeframe should contact their healthcare provider

The consultation also includes a personalized recommendation for laboratory testing to ensure that compounded semaglutide therapy is safe and appropriate for the patient

In March 2026, Aardvark Therapeutics announced that the US FDA had placed a full clinical hold on its investigational new drug application for ARD-101 related to the Companys previously announced voluntary pause

This analysis is a follow-up to research presented by Prime/MRx in 2023, which found that 71 percent of individuals were no longer taking these drugs for weight loss at one year, representing a further 14 percent point decrease in persistence in just one year

Moderate fat is the sweet spot